Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 22Breast Neoplasms 21Neoplasms 10Brain Neoplasms 10Glioma 8Head and Neck Neoplasms 7Lymphoma 6Colonic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Glioblastoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Spinal Cord Neoplasms 3Lung Neoplasms 3Stomach Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Neurofibromatosis 1 2Neoplasm Metastasis 2Multiple Myeloma 2Meningioma 2Lymphoma, B-Cell 2Liver Neoplasms 2

Interventions

Peripheral Blood Stem Cell Transplantation 26Rituximab 20Cyclophosphamide 18fludarabine phosphate 17Mycophenolic Acid 16Tacrolimus 14Cyclosporine 14Whole-Body Irradiation 12Filgrastim 11Etoposide 10Radiotherapy 8Methotrexate 8Busulfan 8Therapeutics 7Methylprednisolone 7Antilymphocyte Serum 7Cladribine 6Lenalidomide 5Flow Cytometry 5obinutuzumab 4immunotoxin HA22 4Vorinostat 4Vemurafenib 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Ondansetron 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia, Hairy Cell × Magnetic Resonance Imaging × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡